Código QR (código de barras bidimensional)

Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

Currently, there is a crucial need for new treatment approaches to overcome the resistance and intolerance of several tyrosine kinase inhibitor (TKI) therapy lines in chronic myeloid leukemia (CML) patients. Asciminib, the first in its class BCR::ABL1-tyrosine kinase inhibitor specifically targeting...

ver descrição completa

Na minha lista:
Principais autores: A. G. Turkina, Elena Andreevna Kuzmina
Formato: Artigo
Idioma:Russo
Publicado em: Practical Medicine Publishing House 2023-06-01
coleção:Клиническая онкогематология
Assuntos:
chronic myeloid leukemia
tyrosine kinase inhibitors
stamp inhibitors
asciminib
ponatini
t315i mutation
Acesso em linha:https://bloodjournal.ru/index.php/coh/article/view/39
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados